Diagnostic performance of the Xpert MTB/RIF assay in BAL fluid samples from patients under clinical suspicion of pulmonary tuberculosis: a tertiary care experience in a high-tuberculosis-burden area
- PMID: 34008762
- PMCID: PMC8332835
- DOI: 10.36416/1806-3756/e20200581
Diagnostic performance of the Xpert MTB/RIF assay in BAL fluid samples from patients under clinical suspicion of pulmonary tuberculosis: a tertiary care experience in a high-tuberculosis-burden area
Abstract
Objective: To assess the diagnostic performance of the Xpert MTB/RIF assay, a rapid molecular test for tuberculosis, comparing it with that of AFB staining and culture, in BAL fluid (BALF) samples from patients with clinically suspected pulmonary tuberculosis (PTB) who are sputum smear-negative or produce sputum samples of insufficient quantity.
Methods: This was a retrospective study of 140 cases of suspected PTB in patients who were smear-negative or produced insufficient sputum samples and were evaluated at a tertiary teaching hospital in the city of Rio de Janeiro, Brazil. All of the patients underwent fiberoptic bronchoscopy with BAL. The BALF specimens were evaluated by AFB staining, mycobacterial culture, and the Xpert MTB/RIF assay.
Results: Among the 140 patients, results for all three microbiological examinations were available for 73 (52.1%), of whom 22 tested positive on culture, 17 tested positive on AFB staining, and 20 tested positive on the Xpert MTB/RIF assay. The sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy for AFB staining were 68.1%, 96.1%, 88.2%, 87.5%, and 87.6%, respectively, compared with 81.8%, 96.1%, 90.0%, 92.4%, and 91.8%, respectively, for the Xpert MTB/RIF assay. The agreement between AFB staining and culture was 82.3% (kappa = 0.46; p < 0.0001), whereas that between the Xpert MTB/RIF assay and culture was 91.8% (kappa = 0.8; p < 0.0001).
Conclusions: In BALF samples, the Xpert MTB/RIF assay performs better than do traditional methods, providing a reliable alternative to sputum analysis in suspected cases of PTB. However, the rate of discordant results merits careful consideration.
Objetivo:: Avaliar o desempenho diagnóstico do teste Xpert MTB/RIF - teste molecular rápido para tuberculose, comparando-o com o da pesquisa de BAAR e da cultura, em amostras de LBA de pacientes com suspeita clínica de tuberculose pulmonar (TBP) que apresentam baciloscopia de escarro negativa ou produzem amostras com quantidade insuficiente de escarro.
Métodos:: Estudo retrospectivo de 140 casos suspeitos de TBP em pacientes que apresentaram baciloscopia negativa ou produziram amostras de escarro insuficientes e foram avaliados em um hospital-escola terciário na cidade do Rio de Janeiro (RJ). Todos os pacientes foram submetidos à fibrobroncoscopia com LBA. Os espécimes de LBA foram avaliados por meio da realização de pesquisa de BAAR, cultura para micobactérias e teste Xpert MTB/RIF.
Resultados:: Entre os 140 pacientes, resultados de todos os três exames microbiológicos estavam disponíveis para 73 (52,1%), dos quais 22 apresentaram cultura positiva, 17, pesquisa de BAAR positiva, e 20, teste Xpert MTB/RIF positivo. A sensibilidade, especificidade, valor preditivo positivo, valor preditivo negativo e precisão global da pesquisa de BAAR foram de 68,1%, 96,1%, 88,2%, 87,5% e 87,6%, respectivamente, contra 81,8%, 96,1%, 90,0%, 92,4% e 91,8%, respectivamente, do teste Xpert MTB/RIF. A concordância entre a pesquisa de BAAR e a cultura foi de 82,3% (kappa = 0,46; p < 0,0001), enquanto a concordância entre o teste Xpert MTB/RIF e a cultura foi de 91,8% (kappa = 0,8; p < 0,0001).
Conclusões:: Em amostras de LBA, o teste Xpert MTB/RIF tem melhor desempenho do que os métodos tradicionais, fornecendo uma alternativa confiável à análise do escarro em casos suspeitos de TBP. No entanto, a taxa de resultados discordantes merece uma reflexão cuidadosa.
Figures


Similar articles
-
The utility of Xpert MTB/RIF performed on bronchial washings obtained in patients with suspected pulmonary tuberculosis in a high prevalence setting.BMC Pulm Med. 2015 Sep 16;15:103. doi: 10.1186/s12890-015-0086-z. BMC Pulm Med. 2015. PMID: 26377395 Free PMC article.
-
Performance Assessment of Xpert MTB/RIF Assay for Detecting Pulmonary Tuberculosis and Rifampin Resistance in a Tertiary Care Hospital in Korea.Jpn J Infect Dis. 2021 Nov 22;74(6):537-542. doi: 10.7883/yoken.JJID.2020.978. Epub 2021 Mar 31. Jpn J Infect Dis. 2021. PMID: 33790071
-
Combined tests with Xpert MTB/RIF assay with bronchoalveolar lavage fluid increasing the diagnostic performance of smear-negative pulmonary tuberculosis in Eastern China.Epidemiol Infect. 2020 Dec 28;149:e5. doi: 10.1017/S095026882000309X. Epidemiol Infect. 2020. PMID: 33436140 Free PMC article.
-
Usefulness of Mycobacterium tuberculosis-polymerase chain reaction with bronchial washing samples in predicting discontinuation of airborne infection isolation in patients hospitalized with suspected pulmonary tuberculosis.PLoS One. 2022 Dec 30;17(12):e0279256. doi: 10.1371/journal.pone.0279256. eCollection 2022. PLoS One. 2022. PMID: 36584035 Free PMC article. Review.
-
Complicated intrathoracic tuberculosis: Role of therapeutic interventional bronchoscopy.Paediatr Respir Rev. 2023 Mar;45:30-44. doi: 10.1016/j.prrv.2022.12.001. Epub 2022 Dec 17. Paediatr Respir Rev. 2023. PMID: 36635200 Review.
Cited by
-
Performance of Xpert MTB/RIF and acid-fast bacilli smear microscopy for the diagnosis of pulmonary tuberculosis using bronchoalveolar lavage samples in negative or sputum-scarce adults in Colombia: a retrospective diagnostic accuracy study.BMC Infect Dis. 2025 Apr 9;25(1):491. doi: 10.1186/s12879-025-10856-z. BMC Infect Dis. 2025. PMID: 40205580 Free PMC article.
-
Tuberculosis Series 2021.J Bras Pneumol. 2021 Apr 30;47(2):e20210109. doi: 10.36416/1806-3756/e20210109. J Bras Pneumol. 2021. PMID: 33950097 Free PMC article. No abstract available.
-
The Role of GeneXpert® for Tuberculosis Diagnostics in Brazil: An Examination from a Historical and Epidemiological Perspective.Trop Med Infect Dis. 2023 Oct 26;8(11):483. doi: 10.3390/tropicalmed8110483. Trop Med Infect Dis. 2023. PMID: 37999602 Free PMC article.
References
-
- World Health Organization . Global tuberculosis report 2019. Geneva: World Health Organization; https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-en...
-
- Brasil. Ministério da Saúde . Manual de para o Controle da Tuberculose. Brasília: Ministério da Saúde; 2019.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical